2023
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
Lee T, Aisner D, David M, Eno C, Gagan J, Gocke C, Guseva N, Haley L, Jajosky A, Jones D, Mansukhani M, Mroz P, Murray S, Newsom K, Paulson V, Roy S, Rushton C, Segal J, Senaratne T, Siddon A, Starostik P, Van Ziffle J, Wu D, Xian R, Yohe S, Kim A. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances 2023, 7: 4599-4607. PMID: 37236162, PMCID: PMC10425685, DOI: 10.1182/bloodadvances.2023010149.Peer-Reviewed Original ResearchConceptsMolecular testingAcute casesHematologic malignanciesRapid turnaround timeTertiary care laboratoryAcute myeloid leukemiaCurrent clinical practiceMyeloid leukemiaTurnaround timeLymphoid processesClinical practicePatient careNGS panelCalendar daysClinical expectationsWorking Group ReportMost survey respondentsMalignancyCareReimbursementCase reimbursementSurvey respondentsGroup ReportTesting practicesDays
2020
Evaluation of Positive B- and T-Cell Gene Rearrangement Studies in Patients With Negative Morphology, Flow Cytometry, and Immunohistochemistry
Mendoza H, Tormey CA, Siddon AJ. Evaluation of Positive B- and T-Cell Gene Rearrangement Studies in Patients With Negative Morphology, Flow Cytometry, and Immunohistochemistry. Archives Of Pathology & Laboratory Medicine 2020, 145: 227-230. PMID: 32886749, DOI: 10.5858/arpa.2019-0663-oa.Peer-Reviewed Original ResearchConceptsGene rearrangement studiesBone marrow studyRearrangement studiesMarrow studiesLymphoproliferative disordersTCR gene rearrangement studiesT-cell receptor gene rearrangement studiesT-cell gene rearrangement studiesNegative bone marrowPeripheral blood findingsIg gene rearrangement studiesPeripheral blood assaysGene rearrangement resultsDate of testingHematologic outcomesBlood findingsFinal diagnosisPositive BSHematologic malignanciesMedical recordsPositive immunoglobulinSubsequent diagnosisBlood assaysDisease processBone marrow
2018
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restriction